Compounded Topical Dutasteride

Androgenetic alopecia affects roughly 80 percent of men and 50 percent of women over their lifetime, and while not life-threatening, it can cause significant psychological distress.¹ There are a variety of treatments for combating hair loss, and the right combination can help prevent further hair loss and even promote hair regrowth. This blog post will provide an overview of one such therapy – compounded topical dutasteride 0.05% – as well as a comparison to oral formulations and how it can be combined with minoxidil to prevent hair loss and maximize a patient’s hair regrowth.

Dutasteride vs. Finasteride

Oral finasteride is an approved 5-alpha reductase inhibitor for male androgenetic alopecia. Dutasteride is also a 5-alpha-reductase inhibitor that is FDA-approved to treat benign prostatic hyperplasia at 0.5 mg/day, and it is also commonly prescribed off-label to treat androgenic alopecia. 

Both medications suppress the formation of DHT, the androgen that causes hair follicles to shrink, leading to eventual hair loss. However, dutasteride is more potent and suppresses dihydrotestosterone (DHT) by more than 90 percent compared with about 70 percent with finasteride.² In one study, dutasteride showed greater impact than finasteride in treating male androgenetic alopecia and had similar adverse events, showing that dutasteride may provide a more viable option for male patients.³

Topical vs. Oral Dutasteride

Due to its much stronger effect on DHT suppression and much longer half-life,⁴ oral dutasteride can cause systemic side effects such as sexual dysfunction, including low libido, impotence, and gynecomastia. There is limited published data for topical application, but as with many other medications, topical application of dutasteride can directly target hair follicles while minimizing its systemic exposure.⁵ Some pharmacokinetic data have demonstrated minimal bloodstream levels and DHT changes with topical therapy compared to oral therapy.⁶ 

Compounded Topical Dutasteride Dosage

Prescribers can begin at 0.05% as a conservative dose to assess tolerability, especially if combining with other drugs such as minoxidil. Higher concentrations (0.1% and 0.5%) may be used, but these higher strengths might increase systemic absorption.

One such study in men observed that a 0.1% topical dutasteride solution applied twice weekly for six months led to a significant increase in their hair count and thickness.⁷ Another report found that women using a topical dutasteride gel once daily for six months had a significant reduction in serum DHT levels accompanied by hair regrowth.⁷ 

Although these early topical-use studies lack placebo controls, they demonstrate that 0.05–0.1% dutasteride applied to the scalp can penetrate and stimulate hair growth in both men and women.

Women and Dutasteride

Although less studied in women, 0.15 mg daily dutasteride resulted in increased hair thickness in women under 50 with androgenetic alopecia over a period of three years.⁸ Dutasteride is contraindicated during pregnancy because it may inhibit the development of the male fetus’s external genitalia.⁹ Because dutasteride is absorbed through the skin, women who are pregnant or trying to become pregnant shouldn’t touch dutasteride.

Use in Combination with Minoxidil

While formal trials testing topical dutasteride and minoxidil versus monotherapy have not been published, adding minoxidil’s results (increasing hair shaft diameter and length, maintaining follicles in the anagen phase) to dutasteride is expected to result in greater overall improvements than the individual therapies.

Why Choose VLS Pharmacy & New Drug Loft?

Compounded topical dutasteride 0.05% is an off-label therapy that offers prescribers a way to leverage dutasteride’s powerful DHT-blocking effect for androgenetic alopecia with potentially fewer systemic side effects. By localizing treatment to the scalp, this route can improve hair growth while potentially preventing systemic DHT suppression. We offer topical sprays and drops of dutasteride at a dose of 0.05%.

By working closely with a 503A compounding pharmacy, providers can ensure that their topical dutasteride is precisely tailored to the specific needs of individual patients. Our topical dutasteride is compounded in a sterile compounding facility that is USP chapters <795>, <797>, and <800> compliant.

 

Please comment below with any thoughts or questions.

Reach out to our team to learn about best practices and to partner with our experts on custom compounded medications for your patients. All medications from VLS Pharmacy and New Drug Loft are prepared in a lab that follows safety and quality standards per our status as a 503A pharmacy.

 

References

 

1. Ho CH, Sood T, Zito PM. Androgenetic Alopecia. In: StatPearls. StatPearls Publishing; 2025. Accessed July 2, 2025. http://www.ncbi.nlm.nih.gov/books/NBK430924/
2. Nickel JC. Comparison of Clinical Trials With Finasteride and Dutasteride. Rev Urol. 2004;6(Suppl 9):S31-S39.
3. Choi GS, Sim WY, Kang H, et al. Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study. Ann Dermatol. 2022;34(5):349-359. doi:10.5021/ad.22.027
4. Estill MC, Ford A, Omeira R, Rodman M. Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects. Georget Med Rev. 2023;7(1). doi:10.52504/001c.88531
5. Hussein RS, Dayel SB, Abahussein O, El‐Sherbiny AA. Applications and efficacy of minoxidil in dermatology. Skin Health Dis. 2024;4(6):e472. doi:10.1002/ski2.472
6. Topical Dutasteride Clinical Trial Results. XYON. Accessed July 2, 2025. https://xyonhealth.com/blogs/library/topical-dutasteride-clinical-trial-results
7. Topical Dutasteride. American Hair Loss Association. Accessed July 2, 2025. https://www.americanhairloss.org/hair-loss-treatment/drug-therapy/topical-dutasteride/
8. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014;80(6):521-525. doi:10.4103/0378-6323.144162
9. Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatol Treat. 2022;33(7):2946-2962. doi:10.1080/09546634.2022.2109567

 

 

---

 

Read More…

• Learn more about our compounding capabilities for hair loss
• A deep dive into other hair loss prevention and regrowth treatment options
• It’s never been easier to submit your prescriptions! Place your order today

 

DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE. The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site intends to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.